The conversation in the surgical ICU happens the same way every time.
“His creatinine spiked post-op, but it came back down before discharge. The labs look normal now. The kidney recovered.”
Cardiac surgeons hear this reassurance so often it’s become standard. The patient leaves the hospital with normal kidney function on the discharge summary. By every conventional metric, the surgery was a success. The acute kidney injury was resolved.
Except it didn’t. Not really.
The real cost of “normal” creatinine
A 2023 study in JAMA Network Open followed over 40,000 hospitalized patients who fit this profile: no prior chronic kidney disease, reduced kidney function during admission, discharged with “normal” kidney function. On paper, their kidneys recovered.
What actually happened was sobering. In the year after discharge, mortality was 18 percent higher in patients who experienced that transient kidney stress, even after adjustment for age, diabetes, heart failure, and every other comorbidity you’d expect to drive mortality risk.
They hadn’t recovered. Their kidneys had been scarred by the event in ways that a single creatinine measurement couldn’t capture.
This is the hidden reality of post-operative acute kidney injury: the clinical threshold we use to declare “recovery”, a serum creatinine that returns to normal. It is not the same as true kidney recovery. A kidney that has been through acute stress during surgery carries that injury forward, initially silently, for life.
The Chronic Renal Insufficiency Cohort Study (CRIC) makes this pattern unmistakable. Researchers tracked over 1,000 patients who progressed to dialysis and another 710 who died before reaching that threshold. The hospitalization data tells a clear story: Admission rates remain relatively stable for years, then accelerate sharply. In the five years leading up to end-stage kidney disease (ESKD) or death, hospitalizations double. In the final two years, the acceleration becomes steep. The cascade is visible, predictable, and by the time it’s obvious, largely irreversible.
These patients didn’t suddenly become sick. They had accumulated a series of kidney insults, some acute, some chronic, that gradually eroded their functional reserve. But what’s critical is that most of these escalating hospitalizations are not labeled as “kidney” admissions. They present as heart failure exacerbations, infections, electrolyte imbalances, or hypertensive crises. So, the body fails in ways that may appear unrelated to kidney disease but aren’t. Each hospitalization signals further loss of renal reserve until the trajectory becomes untenable.
The intervention window we’re missing
Here’s what cardiac surgeons face every day: Roughly 25 to 30 percent of their patients undergoing coronary artery bypass have pre-existing chronic kidney disease. Their renal functional reserve is already diminished. When the heart-lung machine activates, blood flow to the kidney drops. Inflammatory mediators surge. Oxidative stress peaks. The kidney, already struggling to keep up, can’t handle the extra stress.
But what if we could support the kidney during these times of stress? What if we could sustain the kidney so it doesn’t lose additional function?
Recent feasibility data published in the Annals of Thoracic Surgery examined this exact question. Researchers looked at cardiac surgery patients with impaired kidney function and provided perioperative renal support, not waiting for complications to appear.
The results were promising: On-treatment kidney function (measured creatinine clearance) increased by 70 percent during the timeframe when the insult silently builds. More importantly: There were no 30-day readmissions. This is not yet proven in a large, randomized trial, but the signal is clear: A fundamentally new approach to an old problem is showing promise and warrants rigorous testing.
Why this reframes the economics
From a hospital economics perspective, this distinction matters enormously. Under traditional fee-for-service, post-operative complications impacted Diagnosis-Related Group (DRG) margins. Under emerging bundled-payment models like the Centers for Medicare and Medicaid Services (CMS) Transforming Episode Accountability Model (TEAM), which began in January 2026, the DRG includes the total 30-day episode of care. Hospitals participating in TEAM face a 1.5 percent payment reduction on cardiac surgery DRGs and must absorb the costs of all care for the next 30 days, including ICU days, skilled nursing facility (SNF) placement, 30-day readmissions, and even dialysis starts.
A single high-risk CKD patient who develops post-operative AKI can easily cost a hospital $18,000 to $25,000 in lost margin through extended ICU stays alone. Add the downstream readmissions, SNF, and dialysis costs, and those figures can balloon out of control. The economics shift from “manage the complication” to “prevent it in the first place.”
The real timing problem
What’s remarkable about the cardiac surgery story is just how often patients leave the hospital without the kidneys they came in with. The implications for their future care are underappreciated. This is why the CRIC data is so fascinating. Those escalating hospitalization rates in the years before ESKD or death represent the cumulative toll of repeated kidney insults that were “managed” but never truly prevented. Each transient spike in creatinine that “came back down” was quietly stealing function. For many, that first hit was cardiac surgery. Their destination? Acute heart failure, death, or dialysis.
What comes next
The GRADIENT pivotal trial, now enrolling at sites across the U.S. and Europe, will test whether earlier intervention during cardiac surgery can sustain or enhance kidney function in a rigorous, randomized fashion. The hypothesis is straightforward: If we can sustain kidney function during the window when it matters most, we can alter the disease trajectory, not just manage its complications.
For cardiac surgeons, this represents a genuine shift in how we think about post-operative kidney management. The question changes from “how do we treat AKI after it happens” to “how do we prevent it from developing in the first place.” The patients who benefit most are the ones already at highest risk: the 25 to 30 percent with pre-existing kidney disease, the ones whose renal reserve is likely already lost, the ones for whom a transient post-operative kidney injury can mean the difference between years of independent kidney function or progressive decline.
The reassurance “she left with the kidney she came in with” only works if we’re honest about what that actually means. For too many patients, it means a kidney that survived the surgery but was scarred by it and will be more likely to repeat during the next admission.
What if we stopped accepting that outcome as inevitable?
John Erbey is the CEO and founder of Roivios, a medical technology company advancing solutions to sustain kidney function during acute clinical stress. He holds a Doctor of Philosophy from the University of Pittsburgh, is a Delta Omega member, and has more than 25 years of leadership in medical device development and health care innovation.
His work focuses on the clinical and economic impact of timing in kidney preservation during high-risk surgical moments. Roivios is currently advancing this research through the BIPASS Study and the GRADIENT Trial, with additional work outlined on the company’s studies page.
He shares updates on LinkedIn and through the Roivios company page.
